Diode laser 532nm Facial Spider Vein Removal

Diode pumped 532nm Green Laser is the new versatile and effective system for the non-invasive treatment of vascular and pigmented lesions such as: face and lower-limb angiotelectasia, cayenne-pepper spots, red angiomas, flat surface angiomas, rosacea, spider naevus, freckles, keratoderma, dermatosis, etc...

Thanks to the high radiation absorption coefficient at 532nm by the oxyhemoglobin, 532nm laser is able to perform a real selective photothermolysis on vascular lesions without injuring the surrounding capillaries and thus preventing that purple effect often unacceptable for patients with aesthetic lesions.

Advantages 

1. Most advanced technology diode pumped 532nm laser.

2. Professional designed treatment headpiece, to enable the treatment safe and effective.

3. CW, Pulse treatment models.

4. 5/8 Watts max power.

5. Short time operation, no injury, no bleeding.

Applications 

Vascular / Veins / Spider Veins Removal / Nevus Flammeus / face and lower-limb angiotelectasia / cayenne-pepper spot / red angiomas / flat surface angiomas / rosacea / spider naevus / freckles / keratoderma / dermatosis

Acne rosacea: effectiveness of 532 nm laser on the cosmetic appearance of the skin

OBJECTIVE:

The aim of the study was to perform a prospective blinded trial to compare the improvement of midface acne rosacea using 532 nm laser therapy with and without a retinaldehyde-based topical application.

SETTING:

A private clinic and surgicentre specializing in facial plastic surgery.

DESIGN:

A prospective randomized blinded clinical trial.

METHODS:

Fourteen patients with type 1 erythematotelangiectatic acne rosacea were enrolled in the study. The side of the face to be treated was chosen randomly. The opposite side of the face served as the control. Patients underwent six treatments with the 532 nm laser, with four sets of photodocumentation over a period of 3 months. Following each treatment, patients were asked to rate their degree of improvement based on a 5-point improvement scale. A final assessment was performed by five separate blinded evaluators.

MAIN OUTCOME MEASURES:

Final photographic evaluation to assess (1) reduction in overall redness, (2) reduction in visible telangiectasia, (3) difference between left and right sides of the face, and (4) degree of overall skin texture improvement.

RESULTS:

Three men and eight women completed the study. Six right hemifaces and five left hemifaces were treated. One hundred percent of patients noted a mild to moderate improvement in all signs of type 1 acne rosacea, including overall redness of the face, telangiectasia, and skin texture. The blinded evaluators were able to note a difference between the treated and untreated sides 47% of the time.

CONCLUSION:

The 532 nm laser combined with the topical retinaldehyde improved overall redness, telangiectasia, and skin texture in acne rosacea patients. The degree of improvement was greater when compared to using the laser alone as the sole treatment modality.

www.gigaalaser.com

donna@gigaalaser.com

532nm Laser – vascular and pigmentation treatment

The laser treats pigmentation with the 532 nm KTP wavelength.

The energy from this light is selectively absorbed by the melanin that causes pigmentation. This causes a photo-thermal injury to the melanin, and this leads to its disruption and subsequent removal by the body’s immune system. It generally takes 1 to 3 treatments to lighten or remove unwanted pigmentation with the 532nm laser. With most laser pigmentation removal, the pigmentation becomes darker for approximately one week and then flakes off. The treatments are spaced at least 1 month apart. There is also usually some redness and mild swelling in the treatment areas for a few days after treatment.

The laser’s 532nm wavelength does not penetrate very deeply, and therefore pigmentation that is too deep for the laser may not be treatable – for example, melasma, a type of pigmentation caused by the pill or pregnancy, is difficult to treat as it spans many layers of the skin. In some cases it may be appropriate to use the other lasers available at The Victorian Cosmetic Institute to remove pigment. 

Facial Spider Veins or Telangiectasia Treatment by 532nm KTP Laser

These are one of the most common facial skin conditions for which patients seek treatment. These unsightly dilated blood vessels are seen almost exclusively in patients with fair skin, and are often associated with chronic sun exposure, rosacea, overuse of cortisone creams and certain autoimmune diseases, and occasionally they may be hereditary. In many cases, the exact cause is unknown.

Contrary to popular opinion, facial telangiectasia are not associated with alcohol abuse. Unlike leg veins, which are induced and aggravated by gravity, facial telangiectasia are usually capillaries or small arteries (arterioles) in the papillary dermis with weakened elastic fibers in their walls which allow them to dilate and become visible, and despite their common name, they are not true "veins".

They can be classified according to their appearance as linear, arborizing (branching), spider, or punctate telangiectasia. The linear and arborizing type occur most commonly around the nose, and the spider type are most common on the cheeks.

Like most other lasers, the KTP laser makes use of the principle of selective photothermolysis to coagulate abnormal blood vessels while sparing the surrounding tissue. The KTP laser emits a brilliant green light at 532nm, close to a major absorption peak of hemoglobin in blood. The blood absorbs the laser energy more than the surrounding tissue, and by selecting a pulse width less than the thermal relaxation time of the blood vessel, the blood vessel can be selectively coagulated without causing purpura or damaging the skin. No anesthesia is needed for treatment of facial telangiectasia-the laser pulses feel like little "snaps", and can be easily tolerated by most patients. In most cases a transparent cooling gel is applied to the skin to increase comfort and decrease superficial blistering. After the proper laser setting are made, the individual vessels are "traced" with individual laser pulses. If vessels are too small or to numerous to trace, a scanner can be used to treat entire areas. In some cases, the skin may be cooled with ice packs prior to treatment. In some cases, especially in larger, high flow telangiectasia around the nose, there may be an improvement instead of complete resolution. Occasionally, the telangiectasia may at first appear worse than before treatment, and then disappear within a few weeks or months. It is much safer to re-treat than to run the risk of scarring... Anticipate a re-treatment about a month after the initial treatment for best results. Because melanin in skin also absorbs green 532nm light, darker skin can absorb some laser energy, and in some cases, cause mild superficial blistering and crusting ("chicken scratches"), which usually resolves in a few days. Temporary redness and lightening of the skin can occur, especially with higher fluences in darker skinned patients. Scarring is extremely rare with the energy settings used on the face.

Treatment of spider leg veins with the KTP (532 nm) laser—A prospective study

Keywords:

• vascular diameter;
• hyperpigmentation;
• long-pulsed frequency-doubled Neodymium:YAG (Nd:YAG) laser;
• telangiectasias

Abstract

Background and Objectives

Spider leg veins are telangiectasias located intracutaneously. This condition poses a cosmetic problem.

Study Design/Patients and Methods

The purpose of this study was to determine what influence the KTP (532 nm) laser has on spider leg veins dependent on the vascular diameter and to what extent the skin has been affected. Seventy female patients were treated in three laser sessions. Analysis was done 30 weeks after the last laser treatment session.

Results

Fifty-six patients completed the study. In group 1 (vascular diameter ≤ 0.6 mm), spider leg veins were no longer visible in 33%; in 40%, a decrease in vascular diameter could be observed; in 27%, no change in size occurred. In group 2 (vascular diameter 0.7–1.0 mm), laser-treated spider leg veins were visible in all patients. Hyperpigmentation occurred in 13 patients.

Conclusions

The KTP (532 nm) laser is an effective for treating spider leg veins having a vascular diameter under 0.7 mm.

www.gigaalaser.com

donna@gigaalaser.com

532nm KTP Laser Treatment for Facial Veins, Facial Telangiectasia

What are Facial Telangiectasias?

Facial Telangiectasias are broken or dilated blood vessels or capillaries that are commonly found on the face, nose, chin, and cheek. Telangiectasias can also be found on the other parts of the body such as the legs, chest, back, arms, legs, and lower extremities. These facial vessels are typically smaller than a millimeter in diameter and are red to bluish in color.  They are superficially located underneath the skin and are considered vascular lesions that are usually benign.  However, there are some underlying autoimmune diseases that are associated with telengiectasias,  so please consult with a board certified dermatologist to further diagnose any underlying conditions.

What causes facial telangiectasias?

There are several factors which contribute to the development of facial vessels. The most common factors for telangiectasias are the following: genetics, prolonged sun and wind exposure, medications that can dilate vessels, pregnancy, excessive alcohol use, trauma to the skin, surgical incisions, and acne.

Historically, the only surgical treatment available to treat vascular lesions such as facial telangiectasia was electrosurgical desication of the vessel.  This is a sharp needle that delivers an electrical surge of energy that burns through the skin and coagulates the vascular structure underneath the skin.  Though this is effective to remove the lesion, it also can scar the skin surrounding the telangiectsia. As a result of this undesirable scarring of the skin, the VersaPulse laser has proven to be the gold standard to safely treat vascular lesions of the face while minimizing damage to any surrounding tissue.

The 532nm laser is designed to treat various types facial vessels and vascular lesions called facial telangectasia.  One of the specific wavelengths of light to target oxyhemoglobin is the 532nm which is a wavelength offered by the 532nm laser.  This 532nm wavelength precisely targets these vessels with heat- energy.  The targeted oxyhemoglobin (red blood cells) inside the visibly broken capillaries absorb the laser’s energy and are heated up, coagulated, or closed down.  This process is called photothermolysis.

As a result of this light-based energy exchange between the laser and capillary, many patients will experience  clearance of the telangiectasias on the face, nose, chin, and forehead within hours of the initial treatment.  In addition, the thermal effect of the VersaPulse laser on the skin causes the body’s immune response to send scavenger cells, macrophages, to the treatment site.  Therefore, over a period of 3 to 6 weeks, these macrophages work to absorb the treated capillaries, reducing the vascular lesions or facial telangiectasia.  Depending on the severity of these broken vessels, a series of 3 to 4 VersaPulse treatments are recommended.

.......

donna@gigaalaser.com

www.gigaalaser.com

532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Inclusion criteria

• Females or Males, 20 to 80 years of age (inclusive)
• Fitzpatrick Skin Type I - III
• Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea
• Willing to refrain from using systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area
• Must be able to read, understand and sign the Informed Consent Form
• Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions
• Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the face every day for the duration of the study, including the follow-up period
• Willingness to have digital photographs taken of the face
• Agree not to undergo any other procedure for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea during the study
• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study

Exclusion criteria

• History of prior laser or light based procedures for the face within 6 months of study participation
• Fitzpatrick Skin Type IV - VI
• Pregnant and/or breastfeeding
• Subject is less than 20 years of age or greater than 80 years of age
• Having an infection, dermatitis or rash in the treatment area
• Suffering from significant concurrent illness, such as diabetes mellitus, cardiovascular disease, uncontrolled hypertension, or pertinent neurological disorders
• History of keloid formation, hypertrophic scarring or of abnormal wound healing
• History of immunosuppression/immune deficiency disorders such as psoriasis, eczema, vitiligo, or currently using immunosuppressive medications
• Malignant tumors in the target area or history of a malignant skin disease
• History of fibromyalgia
• History of connective tissue disease, such as systemic lupus erythematosus or scleroderma
• Having a known anticoagulative condition or taking prescription anticoagulation medications
• History of seizure disorders due to light
• Any current use of medication that is known to increase sensitivity to light, such as tetracycline
• Having a history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, unless treatment is conducted following a prophylactic regimen
• Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely)
• History of radiation to the head, neck and/or upper chest
• History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation
• Undergoing systemic chemotherapy for the treatment of cancer
• Systemic use of retinoid such as isotretinoin and/or corticosteroid within 6 months
• Topical use of retinoid and/or corticosteroid within 4 weeks of study participation
• Any use of gold therapy for disorders such as rheumatologic disease or lupus
• Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study
• Current smoker or history of smoking within 12 months of study participation
• Participation in a study of another device or drug within 6 months prior to enrollment or during the study
• As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Inclusion criteria

• Females or Males, 20 to 80 years of age (inclusive)
• Fitzpatrick Skin Type I - III
• Clinical diagnosis of Erythematotelangiectatic Rosacea and Papulopustular Rosacea
• Willing to refrain from using systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area
• Must be able to read, understand and sign the Informed Consent Form
• Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions
• Wiling to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the face every day for the duration of the study, including the follow-up period
• Willingness to have digital photographs taken of the face
• Agree not to undergo any other procedure for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea during the study
• Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study

Exclusion criteria

• History of prior laser or light based procedures for the face within 6 months of study participation
• Fitzpatrick Skin Type IV - VI
• Pregnant and/or breastfeeding
• Subject is less than 20 years of age or greater than 80 years of age
• Having an infection, dermatitis or rash in the treatment area
• Suffering from significant concurrent illness, such as diabetes mellitus, cardiovascular disease, uncontrolled hypertension, or pertinent neurological disorders
• History of keloid formation, hypertrophic scarring or of abnormal wound healing
• History of immunosuppression/immune deficiency disorders such as psoriasis, eczema, vitiligo, or currently using immunosuppressive medications
• Malignant tumors in the target area or history of a malignant skin disease
• History of fibromyalgia
• History of connective tissue disease, such as systemic lupus erythematosus or scleroderma
• Having a known anticoagulative condition or taking prescription anticoagulation medications
• History of seizure disorders due to light
• Any current use of medication that is known to increase sensitivity to light, such as tetracycline
• Having a history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area, unless treatment is conducted following a prophylactic regimen
• Having undergone any surgery in the treatment area within 6 months of treatment (or more if skin has not healed completely)
• History of radiation to the head, neck and/or upper chest
• History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation
• Undergoing systemic chemotherapy for the treatment of cancer
• Systemic use of retinoid such as isotretinoin and/or corticosteroid within 6 months
• Topical use of retinoid and/or corticosteroid within 4 weeks of study participation
• Any use of gold therapy for disorders such as rheumatologic disease or lupus
• Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study
• Current smoker or history of smoking within 12 months of study participation
• Participation in a study of another device or drug within 6 months prior to enrollment or during the study
• As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Il GBOX 15 Watt da FisioApulia

E’ attivo il nuovo laser di potenza GBox da 15 watt CW presso lo studio di fisioterapia FISIOAPULIA di Davide del Conte, in via Avellino 24 a Cagnano Varano (FG). Il centro è aperto tutti i giorni dal lunedi al sabato ed ora ha un nuovo strumento per…

Il GBOX 15 Watt da FisioApulia

laserterapia.me